Epigenetic Regulation of BST-2 Expression Levels and the Effect on HIV-1 Pathogenesis

HIV-1 must overcome host antiviral restriction factors for efficient replication. We hypothesized that elevated levels of bone marrow stromal cell antigen 2 (BST-2), a potent host restriction factor that interferes with HIV-1 particle release in some human cells and is antagonized by the viral protein Vpu, may associate with viral control. Using cryopreserved samples, from HIV-1 seronegative and seropositive Black women, we measured in vitro expression levels of BST-2 mRNA using a real-time PCR assay and protein levels were validated by Western blotting. The expression level of BST-2 showed an association with viral control within two independent cohorts of Black HIV infected females (r=-0.53, p=0.015, [n =21]; and r=-0.62, p=0.0006, [n=28]). DNA methylation was identified as a mechanism regulating BST-2 levels, where increased BST-2 methylation results in lower expression levels and associates with worse HIV disease outcome. We further demonstrate the ability to regulate BST-2 levels using a DNA hypomethylation drug. Our results suggest BST-2 as a factor for potential therapeutic intervention against HIV and other diseases known to involve BST-2.

[1]  M. Esteller,et al.  The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  R. Chaisson,et al.  The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individuals. , 2020, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[3]  S. Delany-Moretlwe,et al.  Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial neoplasia in women living with HIV-1 in Africa , 2018, AIDS.

[4]  J. Goedert,et al.  Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells , 2018, Science.

[5]  B. Walker,et al.  Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. , 2018, The lancet. HIV.

[6]  C. Okeoma,et al.  The role of BST‐2/Tetherin in host protection and disease manifestation , 2015, Immunity, inflammation and disease.

[7]  Bianka Mussil,et al.  Increased BST2 expression during simian immunodeficiency virus infection is not a determinant of disease progression in rhesus monkeys , 2015, Retrovirology.

[8]  A. Ryo,et al.  Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy , 2015, Oncotarget.

[9]  T. Ndung’u,et al.  Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor , 2015, Proceedings of the National Academy of Sciences.

[10]  M. Carrington,et al.  Epigenetic regulation of differential HLA-A allelic expression levels. , 2015, Human molecular genetics.

[11]  S. Tsui,et al.  Genome-wide analysis of DNA methylation associated with HIV infection based on a pair of monozygotic twins , 2015, Genomics data.

[12]  Zhiwei Chen,et al.  Whole genome methylation array reveals the down-regulation of IGFBP6 and SATB2 by HIV-1 , 2015, Scientific Reports.

[13]  Melis N. Anahtar,et al.  Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. , 2015, Immunity.

[14]  L. Bierut,et al.  Associations of common variants in the BST2 region with HIV-1 acquisition in African American and European American people who inject drugs , 2015, AIDS.

[15]  N. Borcherding,et al.  Bone Marrow Stromal Antigen 2 (BST-2) DNA Is Demethylated in Breast Tumors and Breast Cancer Cells , 2015, PloS one.

[16]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[17]  A. Iwamoto,et al.  Epigenetic repression of interleukin 2 expression in senescent CD4+ T cells during chronic HIV type 1 infection. , 2015, The Journal of infectious diseases.

[18]  M. Grce,et al.  Epigenetic activation of immune genes in cervical cancer. , 2014, Immunology letters.

[19]  H. Motulsky,et al.  Common misconceptions about data analysis and statistics , 2015, British journal of pharmacology.

[20]  T. Yen,et al.  Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer , 2014, The Laryngoscope.

[21]  M. SkeltonMichelle,et al.  Frequency variation among sub-Saharan populations in virus restriction gene, BST-2 proximal promoter polymorphisms: implications for HIV-1 prevalence differences among African countries. , 2014 .

[22]  W. Klapper,et al.  The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells , 2014, Blood Cancer Journal.

[23]  N. Hu,et al.  BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. , 2014, Current molecular medicine.

[24]  M. Skelton,et al.  Frequency variation among sub-Saharan populations in virus restriction gene, BST-2 proximal promoter polymorphisms: implications for HIV-1 prevalence differences among African countries. , 2014, Omics : a journal of integrative biology.

[25]  T. Ball,et al.  Interferon responses in HIV infection: from protection to disease. , 2014, AIDS reviews.

[26]  P. Jones,et al.  BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. , 2013, Virology.

[27]  M. Muñoz-Fernández,et al.  HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene , 2013, AIDS.

[28]  S. Dairkee,et al.  Aberrant Regulation of the BST2 (Tetherin) Promoter Enhances Cell Proliferation and Apoptosis Evasion in High Grade Breast Cancer Cells , 2013, PloS one.

[29]  P. Jones,et al.  BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). , 2013, Virology.

[30]  S. Kyo,et al.  Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer , 2013, International journal of cancer.

[31]  Lai Wei,et al.  BST2/Tetherin Inhibits Dengue Virus Release from Human Hepatoma Cells , 2012, PloS one.

[32]  X. Van Ostade,et al.  Expression Analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and Tetherin in a Senegalese Cohort of HIV-1-Exposed Seronegative Individuals , 2012, PloS one.

[33]  P. Cannon,et al.  Anti-Tetherin Activities of HIV-1 Vpu and Ebola Virus Glycoprotein Do Not Involve Removal of Tetherin from Lipid Rafts , 2012, Journal of Virology.

[34]  横山 拓平.  Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer , 2012 .

[35]  D. Richman,et al.  Upregulation of BST-2/Tetherin by HIV Infection In Vivo , 2011, Journal of Virology.

[36]  I. Balyasnikova,et al.  The expression of BST2 in human and experimental mouse brain tumors. , 2011, Experimental and molecular pathology.

[37]  Jonathan D. Wren,et al.  Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus , 2011, Epigenetics.

[38]  Clare Jolly,et al.  Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors , 2011, Virology.

[39]  P. Palese,et al.  Budding Capability of the Influenza Virus Neuraminidase Can Be Modulated by Tetherin , 2011, Journal of Virology.

[40]  C. Liang,et al.  BST-2 Diminishes HIV-1 Infectivity , 2010, Journal of Virology.

[41]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[42]  G. Ruthel,et al.  Infectious Lassa Virus, but Not Filoviruses, Is Restricted by BST-2/Tetherin , 2010, Journal of Virology.

[43]  P. Cannon,et al.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment , 2010, Retrovirology.

[44]  P. Cannon,et al.  Ebola Virus Glycoprotein Counteracts BST-2/Tetherin Restriction in a Sequence-Independent Manner That Does Not Require Tetherin Surface Removal , 2010, Journal of Virology.

[45]  A. Moses,et al.  The Great Escape: Viral Strategies to Counter BST-2/Tetherin , 2010, PLoS pathogens.

[46]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[47]  P. Bieniasz,et al.  Human immunodeficiency virus, restriction factors, and interferon. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[48]  T. Ndung’u,et al.  Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. , 2009, The Journal of infectious diseases.

[49]  H. Kräusslich,et al.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. , 2009, Cell host & microbe.

[50]  K. Strebel,et al.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion , 2009, Proceedings of the National Academy of Sciences.

[51]  Wei Wang,et al.  HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody , 2009, Cancer Immunology, Immunotherapy.

[52]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[53]  C. Gray,et al.  Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study , 2008, PloS one.

[54]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[55]  W. Sundquist,et al.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. , 2007, Cell host & microbe.

[56]  Bette Korber,et al.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA , 2004, Nature.

[57]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[58]  B P O'Connor,et al.  Simple and flexible SAS and SPSS programs for analyzing lag-sequential categorical data , 1999, Behavior research methods, instruments, & computers : a journal of the Psychonomic Society, Inc.